Critical Review: Sanofi (SNY) and Its Peers
Sanofi (NYSE: SNY) is one of 114 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Sanofi to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings.
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.2%. Sanofi pays out 28.1% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.4% and pay out 70.6% of their earnings in the form of a dividend.
This table compares Sanofi and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Sanofi||$43.62 billion||$13.09 billion||12.78|
|Sanofi Competitors||$8.02 billion||$2.61 billion||0.18|
Sanofi has higher revenue and earnings than its competitors. Sanofi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Sanofi and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
9.3% of Sanofi shares are held by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Sanofi and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sanofi presently has a consensus price target of $53.50, indicating a potential upside of 6.79%. As a group, “Pharmaceuticals” companies have a potential upside of 22.13%. Given Sanofi’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Sanofi has less favorable growth aspects than its competitors.
Risk & Volatility
Sanofi has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Sanofi’s competitors have a beta of 0.88, indicating that their average stock price is 12% less volatile than the S&P 500.
Sanofi competitors beat Sanofi on 8 of the 15 factors compared.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.